Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
June 7, 2023 2:14 pm ET
Delayed at least 20 minutes

Latest news, events & financials

June 6, 2023

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

June 6, 2023

Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

View all

June 12, 2023

Webcast

Merck & Co., Inc. at the Goldman Sachs 44th Annual Global Healthcare Conference

Add to Calendar Webcast

August 01, 2023

Earnings

Merck & Co., Inc. Q2 2023 Earnings Call

Add to Calendar

October 26, 2023

Earnings

Merck & Co., Inc. Q3 2023 Earnings Call

Add to Calendar

View all

1Q23 Merck Earnings Announcement
PDF

1Q23 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. at the Goldman Sachs 44th Annual Global Healthcare Conference

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

80+

Phase III programs

30+

Under review

10+

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Environmental, Social & Governance (ESG)

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2021/2022 ESG Progress Report

Download our ESG financing documents:

2021 Sustainability financing framework

Second-party opinion (SPO) on the bond framework

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q1 2023 earnings report

Merck’s (NYSE: MRK) Q1 2023 results reflect continued strong underlying performance across key growth drivers, particularly in oncology and vaccines. Our company announced Q1 worldwide sales of $14.5 billion. “Inspired by our commitment to bring bold science forward to address critical unmet patient needs, we began 2023 with significant advancements across our innovative pipeline,” said […]

Next: Our Q1 2023 earnings report